Prospective, randomized, multicenter clinical study comparing a self-expanding covered stent to percutaneous transluminal angioplasty for treatment of upper extremity hemodialysis arteriovenous fistula stenosis
Bart Dolmatch,Timoteo Cabrera,Pablo Pergola,Saravanan Balamuthusamy,Angelo Makris,Randy Cooper,Erin Moore,Jonah Licht,Ewan Macaulay,Geert Maleux,Thomas Pfammatter,Richard Settlage,Ecaterina Cristea,Alexandra Lansky,AVeNEW Trial Investigators,Gerard Goh,Stewart Hawkins,Ian Spark,Rick de Graff,Hannes Deutschmann,Ralph Kickuth,Levester Kirksey,Robert Mendes,John Aruny,Vagar Ali,Deepak Sharma,Himanshu Shah,Amy Dwyer,Dominic Yee,Wang Teng,George Lipkowitz,Theodore Saad,Tim Rogers,Jason Burgess,Jeffrey Hoggard
DOI: https://doi.org/10.1016/j.kint.2023.03.015
Abstract:Use of a covered stent after percutaneous transluminal angioplasty (PTA) was compared to PTA alone for treatment of upper extremity hemodialysis patients with arteriovenous fistula (AVF) stenoses. Patients with AVF stenosis of 50% or more and evidence of AVF dysfunction underwent treatment with PTA followed by randomization of 142 patients to include a covered stent or 138 patients with PTA alone. Primary outcomes were 30-day safety, powered for noninferiority, and six-month target lesion primary patency (TLPP), powered to test whether TLPP after covered-stent placement was superior to PTA alone. Twelve-month TLPP and six-month access circuit primary patency (ACPP) were also hypothesis tested while additional clinical outcomes were observed through two years. Safety was significantly non-inferior while six- and 12-month TLPP were each superior for the covered stent group compared to PTA alone (six months: 78.7% versus 55.8%; 12 months: 47.9% versus 21.2%, respectively). ACPP was not statistically different between groups at six-months. Observed differences at 24 months favored the covered-stent group: 28.4% better TLPP, fewer target-lesion reinterventions (1.6 ± 1.6 versus 2.8 ± 2.0), and a longer mean time between target-lesion reinterventions (380.4 ± 249.5 versus 217.6 ± 158.4 days). Thus, our multicenter, prospective, randomized study of a covered stent used to treat AVF stenosis demonstrated noninferior safety with better TLPP and fewer target-lesion reinterventions than PTA alone through 24 months.